APOE ε4 influences β-amyloid deposition in primary progressive aphasia and speech apraxia

Keith Anthony Josephs, Joseph R. Duffy, Edythe A. Strand, Mary Margaret Machulda, Matthew L. Senjem, Val Lowe, Clifford R Jr. Jack, Jennifer Lynn Whitwell

Research output: Contribution to journalArticle

21 Scopus citations


Background Apolipoprotein E ε4 (APOE ε4) is a risk factor for β-amyloid deposition in Alzheimer's disease dementia. Its influence on β-amyloid deposition in speech and language disorders, including primary progressive aphasia (PPA), is unclear. Methods One hundred thirty subjects with PPA or progressive speech apraxia underwent APOE genotyping and Pittsburgh compound B (PiB) PET scanning. The relationship between APOE ε4 and PiB status, as well as severity and regional distribution of PiB, was assessed. Results Forty-five subjects had an APOE ε4 allele and 60 subjects were PiB-positive. The odds ratio for a subject with APOE ε4 being PiB-positive compared with a subject without APOE ε4 being PiB-positive was 10.2 (95% confidence interval, 4.4-25.5; P <.0001). The APOE ε4 allele did not influence regional PiB distribution or severity. Conclusion APOE ε4 increases the risk of β-amyloid deposition in PPA and progressive speech apraxia but does not influence regional β-amyloid distribution or severity.

Original languageEnglish (US)
Pages (from-to)630-636
Number of pages7
JournalAlzheimer's and Dementia
Issue number6
StatePublished - Nov 1 2014


  • Apolipoprotein
  • Logopenic aphasia
  • Pittsburgh compound B
  • Primary progressive aphasia
  • Speech apraxia

ASJC Scopus subject areas

  • Clinical Neurology
  • Developmental Neuroscience
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Epidemiology
  • Health Policy

Fingerprint Dive into the research topics of 'APOE ε4 influences β-amyloid deposition in primary progressive aphasia and speech apraxia'. Together they form a unique fingerprint.

  • Cite this